TFF Pharmaceuticals Inc. (TFFP)
0.07
-0.09 (-56.98%)
At close: Dec 12, 2024, 9:00 PM
TFF Pharmaceuticals Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
| Revenue | 733.87K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 502.48K | 388.22K | 111.45K | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | 231.39K | -388.22K | -111.45K | n/a | n/a | n/a | n/a | n/a |
| Operating Income | -21.89M | -31.8M | -31.79M | -18.69M | -11.99M | -3.9M | -178.6K | -370.37K |
| Interest Income | n/a | 26.73K | 51.23K | 126.42K | 117.33K | 55.96K | n/a | n/a |
| Pretax Income | -21.24M | -31.77M | -31.04M | -18.57M | -11.87M | -3.84M | -178.6K | -370.37K |
| Net Income | -21.24M | -31.77M | -30.99M | -18.44M | -11.75M | -3.84M | -178.6K | -370.37K |
| Selling & General & Admin | 10.57M | 13.8M | 10.57M | 8.01M | 3.17M | 3.05M | 178.6K | 141.11K |
| Research & Development | 11.56M | 18.5M | 21.3M | 10.68M | 8.82M | 848.81K | n/a | 229.26K |
| Other Expenses | n/a | -495.81K | -88.16K | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 22.63M | 31.8M | 31.79M | 18.69M | 11.99M | 3.9M | 178.6K | 370.37K |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 22.63M | 31.8M | 31.79M | 18.69M | 11.99M | 3.9M | 178.6K | 370.37K |
| Income Tax | n/a | -26.73 | -51.23K | -126.42K | -117.33K | n/a | -52.52K | n/a |
| Shares Outstanding (Basic) | 1.79M | 1.2M | 992.84K | 817.01K | 276.2K | 738.04K | 17.83M | 738.04K |
| Shares Outstanding (Diluted) | 1.79M | 1.2M | 992.84K | 817.01K | 276.2K | 738.04K | 17.83M | 738.04K |
| EPS (Basic) | -11.85 | -26.49 | -31.21 | -22.57 | -42.55 | -5.21 | -0.01 | -0.5 |
| EPS (Diluted) | -11.85 | -26.49 | -31.21 | -22.57 | -42.55 | -5.21 | -0.01 | -0.5 |
| EBITDA | -20.74M | -31.41M | -30.93M | -18.69M | -11.99M | -3.9M | -178.6K | -370.37K |
| Depreciation & Amortization | 502.48K | 388.22K | 111.45K | 206.3K | 171.86K | n/a | 52.52K | n/a |